Ratings LIVENT Nyse

Equities

LTHM

US53814L1089

Delayed Nyse 04:00:13 2024-01-03 pm EST 5-day change 1st Jan Change
16.51 USD -8.53% Intraday chart for LIVENT +140.60% +120.93%

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company's attractive earnings multiples are brought to light by a P/E ratio at 14.67 for the current year.
  • The company appears to be poorly valued given its net asset value.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company's enterprise value to sales, at 4.92 times its current sales, is high.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Specialty Chemicals

1st Jan change Capi. Investor Rating ESG Refinitiv
+120.93% 6.56B
B+
+16.09% 66.26B
A-
-1.86% 47.33B
A-
+15.27% 40.92B
B+
+1.62% 17.76B
C+
+11.35% 16.58B
B+
-10.04% 15.14B
C+
+30.57% 13.41B
A-
-0.95% 9.3B
A
-2.93% 8.55B
A
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes